MX2018004977A - Inhibidores heterociclicos de la proteina cinasa 1 dependiente de 3-fosfoinositido (pdk1) para usarse en el tratamiento del cancer. - Google Patents

Inhibidores heterociclicos de la proteina cinasa 1 dependiente de 3-fosfoinositido (pdk1) para usarse en el tratamiento del cancer.

Info

Publication number
MX2018004977A
MX2018004977A MX2018004977A MX2018004977A MX2018004977A MX 2018004977 A MX2018004977 A MX 2018004977A MX 2018004977 A MX2018004977 A MX 2018004977A MX 2018004977 A MX2018004977 A MX 2018004977A MX 2018004977 A MX2018004977 A MX 2018004977A
Authority
MX
Mexico
Prior art keywords
heterocyclic
treat cancer
pdk1 inhibitors
pdk1
inhibitors
Prior art date
Application number
MX2018004977A
Other languages
English (en)
Inventor
K Hansen Stig
E Binnerts Minke
Original Assignee
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunesis Pharmaceuticals Inc filed Critical Sunesis Pharmaceuticals Inc
Publication of MX2018004977A publication Critical patent/MX2018004977A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen los métodos de uso de los compuestos que inhiben el enlace del sustrato mediado por PIF, de PDK1, que son útiles como inhibidores del crecimiento o la proliferación del cáncer que es dependiente de RSK2 o independiente de AKT. Tambión se describen las composiciones de tales compuestos para usarse en tales métodos de tratamiento del cáncer.
MX2018004977A 2015-10-23 2016-10-21 Inhibidores heterociclicos de la proteina cinasa 1 dependiente de 3-fosfoinositido (pdk1) para usarse en el tratamiento del cancer. MX2018004977A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562245606P 2015-10-23 2015-10-23
PCT/US2016/058255 WO2017070565A1 (en) 2015-10-23 2016-10-21 Heterocyclic pdk1 inhibitors for use to treat cancer

Publications (1)

Publication Number Publication Date
MX2018004977A true MX2018004977A (es) 2018-07-06

Family

ID=57209945

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004977A MX2018004977A (es) 2015-10-23 2016-10-21 Inhibidores heterociclicos de la proteina cinasa 1 dependiente de 3-fosfoinositido (pdk1) para usarse en el tratamiento del cancer.

Country Status (14)

Country Link
US (3) US20190015410A1 (es)
EP (2) EP3763368A1 (es)
JP (1) JP7094879B2 (es)
KR (1) KR20180101329A (es)
CN (1) CN108697699A (es)
AU (2) AU2016342352B2 (es)
BR (1) BR112018008025A2 (es)
CA (1) CA3002907A1 (es)
DK (1) DK3364971T3 (es)
ES (1) ES2820770T3 (es)
MX (1) MX2018004977A (es)
PL (1) PL3364971T3 (es)
RU (1) RU2018118786A (es)
WO (1) WO2017070565A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4323356A1 (en) 2021-04-13 2024-02-21 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
WO2024040241A1 (en) 2022-08-19 2024-02-22 Viracta Therapeutics, Inc. Pharmaceutical formulations, processes for preparation, and methods of use
WO2024040242A1 (en) * 2022-08-19 2024-02-22 Viracta Therapeutics, Inc. Combinations of pdk1 inhibitors and kinase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
DE102005061655A1 (de) * 2005-12-22 2007-06-28 Merck Patent Gmbh Diazepinone
SI2485731T1 (sl) 2009-10-06 2016-09-30 Millennium Pharmaceuticals, Inc. Heterociklične spojine, ki se uporabljajo kot inhibitorji pdk1
EP2507244B1 (en) * 2009-12-04 2014-11-05 Nerviano Medical Sciences S.r.l. Tricyclopyrazole derivatives
WO2019094779A1 (en) * 2017-11-09 2019-05-16 Sunesis Pharmaceuticals, Inc. Pharmaceutical formulations, processes for preparation, and methods of use

Also Published As

Publication number Publication date
KR20180101329A (ko) 2018-09-12
AU2016342352A1 (en) 2018-05-10
WO2017070565A1 (en) 2017-04-27
EP3364971B1 (en) 2020-06-17
JP2018538244A (ja) 2018-12-27
JP7094879B2 (ja) 2022-07-04
RU2018118786A (ru) 2019-11-26
EP3763368A1 (en) 2021-01-13
CA3002907A1 (en) 2017-04-27
BR112018008025A2 (pt) 2018-10-23
AU2016342352B2 (en) 2022-06-02
US20190015410A1 (en) 2019-01-17
CN108697699A (zh) 2018-10-23
EP3364971A1 (en) 2018-08-29
US20240207258A1 (en) 2024-06-27
RU2018118786A3 (es) 2020-02-25
AU2022203204A1 (en) 2022-06-02
US20230099829A1 (en) 2023-03-30
PL3364971T3 (pl) 2021-05-31
DK3364971T3 (da) 2020-09-21
ES2820770T3 (es) 2021-04-22

Similar Documents

Publication Publication Date Title
MX2023005804A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
MX2022005216A (es) Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
PH12018500177A1 (en) Compositions useful for treating disorders related to kit and pdfgr
PH12017501925A1 (en) Pyrazole compounds and method for making and using the compounds
CR20190478A (es) Inhibidores de pd-1/pd-l1
PH12017502141A1 (en) Compounds and their methods of use
PH12017502050A1 (en) Naphthyridine compounds as jak kinase inhibitors
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2017006366A (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa.
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
CL2021003513A1 (es) Compuestos heterocíclicos, como inhibidores de bet; composición, útil para tratar cáncer.
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
WO2019023315A3 (en) RAC INHIBITORS
MX2016005393A (es) Metodos para tratar vhc.
MA39824A (fr) Composés azole amido-substitués
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
MX2016016507A (es) Composiciones y metodos para tratar canceres.
MX2018004977A (es) Inhibidores heterociclicos de la proteina cinasa 1 dependiente de 3-fosfoinositido (pdk1) para usarse en el tratamiento del cancer.